Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Jorge E. Cortes, Michael J. Mauro, Alexis Visotcky, Srinivas K Tantravahi, James E Thompson, Jay Yang, Arielle Baim, Yan Gao, Sonia Maldonado-Schmidt, Claire Olig, Kathryn E. Flynn, Jerald P. Radich, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 6601.

https://doi.org/10.1182/blood-2024-207884

Published: 2024

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Michael Mauro, Alexis Visotcky, Kathryn E Flynn, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Jorge E. Cortes, Vamsi K Kota, Srinivas K. Tantravahi, Arielle Baim, Mei-Jie Zhang, Alexander Hinman, Ehab L. Atallah, Kendra Sweet

Blood (2022) 140 (Supplement 1): 6765–6766.

https://doi.org/10.1182/blood-2022-160138

Published: 2022

Journal Articles

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Ehab L. Atallah, Alexis Visotcky, Kathryn E Flynn, Mei-Jie Zhang, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Srinivas K. Tantravahi, B. Douglas Douglas Smith, Javier Pinilla Ibarz, Kendra Sweet, Michael Mauro, Brian J. Druker, James E. Thompson, Sonia Maldonado-Schmidt, Arielle Baim, Charles A. Schiffer, Vamsi K. Kota, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3885–3886.

https://doi.org/10.1182/blood-2022-160172

Published: 2022

Journal Articles

Exploring Interest in and Feasibility of a Lifestyle Intervention for Multiple Myeloma Patients

Abigail Kerschner, Allen Hodge, Alexis Williams, Patrica Sheean, Kathleen Jensik, Alexis Visotcky, Parameswaran Hari, Meera Mohan, Saurabh Chhabra, Anita D'Souza, Melinda Stolley

Blood (2021) 138 (Supplement 1): 4018.

https://doi.org/10.1182/blood-2021-148134

Published: 2021

Journal Articles

Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study

Saurabh Chhabra, MD, Parameswaran Hari, MD MRCP, MS, Alexis Visotcky, Nirav N Shah, MD, J. Douglas Rizzo, MD, Wael Saber, MD MS, Anita D'Souza, MBBS, Binod Dhakal, MBBS, Ashish Anshu, MS, PhD, Robert Thompson, Timothy S. Fenske, MD, Bronwen E. Shaw, PhD MRCP, FRCPath, William R. Drobyski, MD, Marcelo C. Pasquini, MD, Mehdi Hamadani, MD

Blood (2017) 130 (Supplement 1): 1974.

https://doi.org/10.1182/blood.V130.Suppl_1.1974.1974

Published: 2017

NARROW

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Exploring Interest in and Feasibility of a Lifestyle Intervention for Multiple Myeloma Patients

Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study

Email alerts

ASH Publications

American Society of Hematology

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Exploring Interest in and Feasibility of a Lifestyle Intervention for Multiple Myeloma Patients

Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only